Skip to main content
SpringerLink
Log in

Male Reproductive Endocrinology

  • Chapter
Challenging Cases in Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 182 Accesses

Abstract

This 23-yr-old man was referred to our Endocrinology Clinic for the management of adrenal insufficiency. The patient was born of a full-term uncomplicated delivery, and grew up normally in early childhood. At 6 yr of age, he became ill, stopped growing, and developed increased pigmentation of the skin. He was evaluated at a local hospital in Mexico and diagnosed as having adrenal insufficiency. After initiation of glucocorticoid replacement therapy with 5 mg prednisone daily, his condition improved and growth resumed, but the increased skin pigmentation persisted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brandon DD, Isabelle LM, Samuels MH, Kendall JW, Loriaux DL. Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Steroids 1999; 64: 372–378.

    Article  PubMed  CAS  Google Scholar 

  2. Jeffcoate W. Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency. Ann Clin Biochem 1999; 36: 151–157.

    PubMed  CAS  Google Scholar 

  3. Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, Weetman AP. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997; 46: 255–261.

    Article  CAS  Google Scholar 

  4. Valero MA, Leon M, Ruiz Valdepenas MP, Larrodera L, Lopez MB, Papapietro K, Jara A, Hawkins F. Bone density and turnover in Addison’s disease: effect of glucocorticoid treatment. Bone Miner 1994; 26: 9–17.

    Article  PubMed  CAS  Google Scholar 

  5. Obermayer-Straub P, Manns MP. Autoimmune polyglandular syndromes. Baillieres Clin Gastroenterol 1998; 12: 293–315.

    Article  PubMed  CAS  Google Scholar 

  6. Pfaffle RW, Blankenstein O, Wuller S, Kentrup H. Combined pituitary hormone deficiency: role of Pit-1 and Prop-1. Acta Paediatr Suppl 1999; 88: 33–41.

    Article  PubMed  CAS  Google Scholar 

  7. Castrillo JL, Theill LE, Karin M. Function of the homeodomain protein GHF1 in pituitary cell proliferation. Science 1991; 253: 197–199.

    Article  PubMed  CAS  Google Scholar 

  8. Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Martensson IL, et al. Mutations in the homeobox gene HESXI/Hesxl associated with septo-optic dysplasia in human and mouse. Nat Genet 1998; 19: 125–133.

    Article  PubMed  CAS  Google Scholar 

  9. Parks JS, Brown MR. Transcription factors regulating pituitary development. Growth Horm IGF Res 1999; 9 (Suppl B): 2–8.

    Article  PubMed  CAS  Google Scholar 

  10. Parks JS, Brown MR, Hurley DL, Phelps CJ, Wajnrajch MP. Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999; 84: 4362–4370.

    Article  PubMed  CAS  Google Scholar 

  11. Pfaffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, et al. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992; 257: 1118–1121.

    Article  PubMed  CAS  Google Scholar 

  12. Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992; 257: 1115–1118.

    Article  PubMed  CAS  Google Scholar 

  13. Semina EV, Reiter R, Leysens NJ, Alward WL, Small KW, Datson NA, et al. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet 1996; 14: 392–399.

    Article  PubMed  CAS  Google Scholar 

  14. Wu W, Cogan JD, Pfaffle RW, Dasen JS, Frisch H, O’Connell SM, et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998; 18: 147–149.

    Article  PubMed  CAS  Google Scholar 

  15. Sadeghi-Nejad A, Senior B. Autosomal dominant transmission of isolated growth hormone deficiency in iris-dental dysplasia (Rieger’s syndrome). J Pediatr 1974; 85: 644–648.

    Article  PubMed  CAS  Google Scholar 

  16. Seminara SB, Hayes FJ, Crowley WF Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’ s syndrome): pathophysiological and genetic considerations. Endocr Rev 1998; 19: 521–539.

    Article  PubMed  CAS  Google Scholar 

  17. Reutens AT, Achermann JC, Ito M, Ito M, Gu WX, Habiby RL, et al. Clinical and functional effects of mutations in the DAX-1 gene in patients with adrenal hypoplasia congenita. J Clin Endocrinol Metab 1999; 84: 504–511.

    Article  PubMed  CAS  Google Scholar 

  18. Kaiserman KB, Nakamoto JM, Geffner ME, McCabe ER. Minipuberty of infancy and adolescent pubertal function in adrenal hypoplasia congenita. J Pediatr 1998; 133: 300–302.

    Article  PubMed  CAS  Google Scholar 

  19. Binder G, Wollmann H, Schwarze CP, Strom TM, Peter M, Ranke MB. X-linked congenital adrenal hypoplasia: new mutations and long-term follow-up in three patients. Clin Endocrinol (Oxf) 2000; 53: 249–255.

    Article  CAS  Google Scholar 

  20. Tabarin A, Achermann JC, Recan D, Bex V, Bertagna X, Christin-Maitre S, et al. A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 2000; 105: 321–328.

    Article  PubMed  CAS  Google Scholar 

  21. Goodfellow PN, Camerino G. DAX-1, an ‘antitestis’ gene. Cell Mol Life Sci 1999; 55: 857–863.

    PubMed  CAS  Google Scholar 

  22. Burris TP, Guo W, McCabe ER. The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Recent Prog Horm Res 1996;51:241–259; discussion 259–260.

    Google Scholar 

  23. Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E, Moser C, Walker AP, McCabe ER, et al. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 1994; 372: 635–641.

    Article  PubMed  CAS  Google Scholar 

  24. Lipworth BJ. Systemic adverse effects of inhaled corticosteroids therapy: a systemic review and meta-analyses. Arch Int Med 1999; 159: 941–955.

    Article  CAS  Google Scholar 

  25. Walsh P, Aeling JL, Huff L, and Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29: 501–503.

    Article  PubMed  CAS  Google Scholar 

  26. Homer JJ, Gazis TG. Cushing’s syndrome induced by betamethasone nose drops: in rhinological disease betamethasone should be regarded as systemic corticosteroid. Br Med J 1999; 318: 1355–1357.

    Article  CAS  Google Scholar 

  27. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the e hypothalamic-pituitary-adrenal axis. J Aller Clin Immunol 1998; 102: 191–197.

    Article  CAS  Google Scholar 

  28. Taylor AV, Laoprasert N, Zimmerman D, and Sachs MI. Adrenal suppression secondary to inhaled fluticasone propionate. Ann Aller Asthma Immunol 1999; 83: 68–70.

    Article  CAS  Google Scholar 

  29. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA 1999; 282: 671–676.

    Article  PubMed  CAS  Google Scholar 

  30. Laroche M, Porteau L, et al. Osteoporotic vertebral fractures in a man under high-dose inhaled glucocorticoid therapy. A case-report with review of literature. Rev Rhum Engl Ed 1997; 64: 267–270.

    PubMed  CAS  Google Scholar 

  31. Young CA, Williams IR, and McFarlane IA. Unrecogonized Cushing’s syndrome and adrenal suppression due to topical clobetasol propionate. Br J Clin Pract 1991; 45: 61–62.

    PubMed  CAS  Google Scholar 

  32. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Superpotent topical corticosteroid use with adrenal suppression: clinical considerations. J Am Acad Derm 1998; 38: 318–321.

    Article  PubMed  CAS  Google Scholar 

  33. MacAdams MR, White RH, and Bradley CE. Reduction in serum testosterone levels during chronic glucocorticoid therapy. Ann Int Med 1986; 104: 648–646.

    PubMed  CAS  Google Scholar 

  34. McKenna TJ, Lorber D, Lacroix A, Rabin D. Testicular activity in Cushing’ s disease. Acta Endocrinol (Copenh) 1979; 91: 501–510.

    CAS  Google Scholar 

  35. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 1997; 137: 209–217.

    Article  PubMed  CAS  Google Scholar 

  36. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382–4389.

    Article  PubMed  CAS  Google Scholar 

  37. Kim CH, Cheng SL, Kim GS. Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss. J Endocrinol 1999; 162: 371–379.

    Article  PubMed  CAS  Google Scholar 

  38. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274–282.

    Article  PubMed  CAS  Google Scholar 

  39. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202–211.

    Article  PubMed  CAS  Google Scholar 

  40. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292–299.

    Article  PubMed  CAS  Google Scholar 

  41. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001; 16: 104–112.

    Article  PubMed  CAS  Google Scholar 

  42. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173–1177.

    Article  PubMed  CAS  Google Scholar 

  43. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology task force on osteoporosis guidelines. Arthritis Rheumat 1996; 39: 1791–1801.

    Article  Google Scholar 

  44. Albano MC, Latronico AC, Arnhold IJ, Domenice S, Bloise W, Mendonca BB. Long-acting GnRH agonists in the differential diagnosis of male precocious puberty. J Pediatr Endocrinol Metab 1997; 105: 499–503.

    Google Scholar 

  45. Apter D. Ultrasensitive new immunoassays for gonadotropins in the evaluation of puberty. Curr Opin Pediatr 1993; 5: 481–487.

    PubMed  CAS  Google Scholar 

  46. Garibaldi LR, Aceto T Jr, Weber C, Pang S. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. J Clin Endocrinol Metab 1993; 76: 851–856.

    Article  PubMed  CAS  Google Scholar 

  47. Lauue L. Ligand-independent hormone secretion. Curr Opin Pediatr 1995; 7: 434–439.

    Article  Google Scholar 

  48. DiMeglio LA, Pescovitz OH. Disorders of puberty: inactivating and activating molecular mutations. J Pediatr 1997; 131 (1 Pt 2): S8 - S12.

    PubMed  CAS  Google Scholar 

  49. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992; 89: 5152–5156.

    Article  PubMed  CAS  Google Scholar 

  50. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688–1695.

    Article  PubMed  CAS  Google Scholar 

  51. Latronico AC, Lins TS, Brito VN, Arnhold IJ, Mendonca BB. The effect of distinct activating mutations of the luteinizing hormone receptor gene on pituitary-gonadal axis in both sexes. Clin Endocrinol (Oxf) 2000; 53: 609–613.

    Article  CAS  Google Scholar 

  52. Kremer H, Martens JW, van Reen M, Verhoef-Post M, Wit JM, Otten BJ, et al. A limited repertoire of mutations of the LH receptor gene in familial and sporadic patients with male LH-independent precocious puberty. J Clin Endocrinol Metab 1999; 84: 1136–1140.

    Article  PubMed  CAS  Google Scholar 

  53. Wu SM, Leschek EW, Rennert OM, Chan WY. Luteinizing hormone receptor mutations in disorders of sexual development and cancer. Front Biosc 2000; 5: D343 - D352.

    Article  CAS  Google Scholar 

  54. Bertelloni S, Baroncelli GI, Lala R, Cappa M, Matarazzo P, De Sanctis C, Saggese G. Long-term outcome of male-limited gonadotropic-independent precocious puberty. Horm Res 1997; 48: 235–239.

    Article  PubMed  CAS  Google Scholar 

  55. Martin MM, Wu SM, Martin AL, Rennert OM, Chan WY. Testicular seminoma in a patient with a constitutively activating mutation of the luteinizing hormone/chorionic gonadotropin receptor. Eur J Endocrinol 1998; 139: 101–106.

    Article  PubMed  CAS  Google Scholar 

  56. Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, Wu SM, Blomberg L, Cutler GB Jr. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci USA 1995; 92: 1906–1910.

    Article  PubMed  CAS  Google Scholar 

  57. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365: 652–654.

    Article  PubMed  CAS  Google Scholar 

  58. Farfel Z, Bourne HR, Liri T. The expanding spectrum of G protein diseases. N Engl J Med 1999; 340: 1012–1020.

    Article  PubMed  CAS  Google Scholar 

  59. Minegishi T, Nakamura K, Takakura K, et al. Cloning and sequencing of human LH/hCG receptor cDNA. Biochem Biophys Res Commun 1990; 172: 1049–1054.

    Article  PubMed  CAS  Google Scholar 

  60. Conway GS. Clinical manifestations of genetic defects affecting gonadotropins and their receptors. Clin Endocrinol 1996; 45: 657–663.

    Article  CAS  Google Scholar 

  61. Hamidinia A, Nold S, Amankwah KS. Localization and treatment of nonpalpable testes. Surg Gynecol Obstet 1984; 159: 439–441.

    PubMed  CAS  Google Scholar 

  62. Bartone FF, Huseman CA, Maizels M, Firlit CF. Pitfalls in using human chorionic gonadotropin stimulation test to diagnose anorchia. J Urol 1984; 132: 563–567.

    PubMed  CAS  Google Scholar 

  63. Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, Gustafson ML, Chang YC, MacLaughlin DT. Measurements of serum mullerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997; 336: 1480–1486.

    Article  PubMed  CAS  Google Scholar 

  64. Forrest MG. Serum mullerian inhibiting substance assay-a new diagnostic test for disorders of gonadal development. N Engl J Med 1997; 336: 1519–1521.

    Article  Google Scholar 

  65. Mendoza-Morfin F, Rodriguez-Lopez M, Oliveros-Rodriguez A, Altamirano-Bustamante P, NavarreteLopez R, Gutierrez-Perez H, Oseguera-Valladares R. Circulating gonadotropin pattern in anorchia syndrome. Response to treatment. Arch Invest Med 1980; 11: 239–247.

    CAS  Google Scholar 

  66. Bernasconi S, Ghizzoni L, Panza C, Volta C, Caselli G. Congenital anorchia: natural history and treatment. Horm Res 1992;37(Suppl 31: 50–54.

    Google Scholar 

  67. Smith NM, Byard RW, Bourne AJ. Testicular regression syndrome-a pathological study of 77 cases. Histopathology 1991; 19: 269–272.

    Article  PubMed  CAS  Google Scholar 

  68. Kulin HE, Santner SJ. The assessment of diminished testicular function in boys of pubertal age. Clin Endocrinol (Oxf) 1986; 25: 283–292.

    Article  CAS  Google Scholar 

  69. Parigi GB, Bardoni B, Avoltini V, Caputo MA, Bragheri R. Is bilateral congenital anorchia genetically determined? Eur J Pediatr Surg 1999; 9: 312–315.

    Article  PubMed  CAS  Google Scholar 

  70. Suzuki Y, Sasagawa I, Izumiya K, Nakada T, Sato J. A genotypic male with anorchia in conjunction with isolated idiopathic hypogonadotropic hypogonadism. Scand J Urol Nephrol 1999; 33: 347–349.

    Article  PubMed  CAS  Google Scholar 

  71. Flett ME, Jones PF, Youngson GG. Emerging trends in the management of the impalpable testis. Br J Surg 1999; 86: 1280–1283.

    Article  PubMed  CAS  Google Scholar 

  72. De Rosa M, Lupoli G, Mennitti M, Zarrilli S, Mirone V, Lombardi G. Congenital bilateral anorchia: clinical, hormonal and imaging study in 12 cases. Andrologia 1996; 28: 281–285.

    Article  PubMed  Google Scholar 

  73. Lobaccaro JM, Medlej R, Berta P, Belon C, Galifer RB, Guthmann JP, Chevalier C, Czernichow P, Dumas R, Sultan C. PCR analysis and sequencing of the SRY sex determining gene in four patients with bilateral congenital anorchia. Clin Endocrinol (Oxf) 1993; 38: 197–201.

    Article  CAS  Google Scholar 

  74. Sasagawa I, Nakada T, Kubota Y, Kato T, Sawamura T. Anorchia associated with gonadotropin deficiency. Urol Int 1993; 51: 231–233.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Shalender Bhasin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atam B. Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Christiansen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, IL, USA

    Mark E. Molitch MD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bhasin, S., Singh, A.B., Christiansen, R. (2002). Male Reproductive Endocrinology. In: Molitch, M.E. (eds) Challenging Cases in Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-277-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-277-7_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-249-0

  • Online ISBN: 978-1-59259-277-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation